Public list: Pharma Startups (6570) Eye Health (703)
Healios K.K. aims to commercialize the world's first pharmaceutical hiPSC derived RPE cell transplantation for treatment of AMD in collaboration with RIKEN, one of the leading research institutes in Japan. The goal of this therapy is to promote the r...Show all
Company (Alive / Active)
Phone: +81-3-3544-8730
Tokyo,
Japan
Per Week | Per Month | Per 6 Months | Per Year | |
---|---|---|---|---|
Rank | Login to see details | |||
Page Views Per Million | Login to see details | |||
Page Views Per User | Login to see details | |||
Reach Per Million | Login to see details |
Investor | Investor Type | Location | Participating Rounds |
---|
Title | Application Date | Patent Date | Status (Patent / Application) |
---|---|---|---|
Eye disease treatment agent, screening method therefor, and method for predicting rejection response associated with retinal pigment epithelial cell transplant | Feb 20, 2015 | Mar 26, 2019 | Patent |
Adapter for cellular medicine container, multi-connection adapter for cellular medicine container, and cellular medicine transfer system and transfer method using same | Nov 27, 2018 | Application | |
Method for producing retinal pigment epithelial cells | Mar 08, 2018 | Application | |
Transplantation medium | Jun 29, 2017 | Application | |
Method for producing retinal pigment epithelial cells | Sep 08, 2016 | Application |